Immunotherapy for Immune-Mediated Cerebellar Ataxia
Start acute immunotherapy immediately with high-dose corticosteroids (or IVIG/PLEX if steroids contraindicated) once infection is ruled out, and escalate rapidly to combination first-line therapy or second-line agents like rituximab if no improvement occurs within 2-4 weeks. 1
First-Line Immunotherapy Approach
The cornerstone of treatment follows a structured algorithmic approach adapted from autoimmune encephalitis guidelines, which apply directly to immune-mediated cerebellar ataxia:
Initial Treatment (First-Line)
- High-dose corticosteroids are the primary first-line agent 1
- Alternative first-line options if steroids contraindicated: IVIG or plasma exchange (PLEX) 1
- For severe presentations, consider combination therapy from the start (steroids + IVIG or steroids + PLEX) rather than sequential therapy 1
Treatment Selection Nuances
When choosing between IVIG vs PLEX as add-on or alternative therapy 1:
- Choose IVIG first in agitated patients and those with bleeding disorders
- Choose PLEX first (5-10 sessions every other day) in patients with:
- Severe hyponatremia
- High thromboembolic risk (cancer, smoking, hypertension, diabetes)
- Associated brain or spinal demyelination
Escalation Strategy
If No Response After First-Line Therapy
Add a second first-line agent (IVIG or PLEX) if no clinical, radiological, or electrophysiological improvement by end of initial treatment cycle 1
If No Response After Combined First-Line Therapy
Escalate to second-line agents within 2-4 weeks if no improvement after combined acute therapy 1:
- Rituximab is the preferred second-line agent for antibody-mediated autoimmunity (chosen by 80% of experts) 1, 2, 3
- Cyclophosphamide for suspected cell-mediated autoimmunity (classical paraneoplastic syndromes) 1
Recent case evidence demonstrates rituximab's effectiveness in refractory cerebellar ataxia, including anti-Sez6L2 antibody-associated cases and seronegative relapsing cases 2, 3. B-cell depletion with rituximab showed clinical improvement with reduction in CSF antibody titers 2.
Critical Timing Principle: "Time is Cerebellum"
Early intervention is paramount - treatment must begin when cerebellar ataxia or atrophy is still mild to preserve "cerebellar reserve" 4. Delayed treatment results in irreversible cerebellar damage and poor outcomes. The therapeutic window is narrow, making rapid diagnosis and immediate immunotherapy initiation essential 4.
Maintenance/Bridging Therapy
After acute treatment response, initiate bridging therapy to prevent relapse 1:
- Gradual oral prednisone taper, OR
- Monthly intravenous immunoglobulin, OR
- Monthly intravenous methylprednisolone
For relapsing cases despite first-line therapy, rituximab consolidation with B-cell monitoring has shown feasibility in preventing recurrence 3.
Common Pitfalls to Avoid
- Delaying treatment while awaiting antibody results: Commercial antibody panels have slow turnaround times and limited sensitivity. Treat based on clinical suspicion; many cases are seronegative 1, 3
- Stopping steroids too early: Premature discontinuation leads to relapse 3. Ensure adequate bridging therapy
- Using only one first-line agent in severe presentations: Combination therapy from the start improves outcomes in severe cases 1
- Waiting too long before escalating to second-line agents: If no response after 2-4 weeks of combined first-line therapy, escalate promptly 1
Diagnostic Workup Before Treatment
Before initiating immunotherapy, rapidly complete 1:
- Brain MRI (may be normal in cerebellar ataxia)
- Lumbar puncture with CSF analysis (cell count, oligoclonal bands, IgG index, neuronal antibodies)
- Serum neuronal antibodies
- Rule out infection based on CSF cell count before starting immunotherapy
- Cancer screening (CT chest/abdomen/pelvis) in appropriate cases